Feprazone, a new anti-inflammatory agent. Studies of potency and gastrointestinal tolerance.
- 1 April 1975
- journal article
- research article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 34 (2) , 190-194
- https://doi.org/10.1136/ard.34.2.190
Abstract
Two studies are reported; a double-blind cross-over trial of feprazone 600 mg daily and aspirin 3.6 g daily in the treatment of rheumatoid arthritis, and an uncontrolled open study of gastrointestinal tolerance in twenty rheumatoid arthritis patients with known intolerance to other drugs. The first study showed that feprazone was significantly superior to aspirin in all the parameters tested. In the second study all twenty patients showed an improvement of their gastrointestinal symptoms, nineteen reporting no symptoms at all when taking the new preparation.Keywords
This publication has 12 references indexed in Scilit:
- A short-term double-blind controlled trial of prenazone (DA 2370) in rheumatoid arthritisCurrent Medical Research and Opinion, 1974
- Clinical study of a new anti-inflammatory drug: 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370).1972
- Clinical trial of 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370) in painful osteoarticular conditions.1972
- Clinical and laboratory evaluation of 4-prenyl-1,2-diphenyl-3,5-pyrazolidinedione (DA 2370) in rheumatoid arthritis and ankylosing spondylitis.1972
- Analgesics and non-steroid anti-inflammatory agents in rheumatic disease.1972
- On the healing properties of esters of D-panthenol with terpene acids, with particular reference to D-pantothenyl trifarnesylacetate.1967
- Long-term Use of Phenylbutazone in Rheumatoid ArthritisBMJ, 1960
- DIAGNOSTIC criteria for rheumatoid arthritis: 1958 revision by a committee of the American Rheumatism Association.1959
- The status of phenylbutazone (butazolidin) in the treatment of rheumatic disorders.1958
- Clinical experience with phenylbutazone in 205 patients.1955